Skip to Content

Science to Secure

Our Future

Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.

Our Science

Aerium is building a pipeline of biologics and small molecule antivirals focused on protecting the world against pandemic and epidemic threats.

Our lead assets are monoclonal antibodies against SARS-CoV-2 with potent neutralizing activity in the laboratory against all variants of concern identified to date, including Delta and Omicron. High resolution structural characterization of the antibodies shows non-overlapping epitopes and a synergistic mechanism of action that makes them potential candidates for the treatment or prophylaxis of COVID-19 and variants that emerge from the currently circulating strains of SARS-CoV-2.

Aerium’s fully integrated discovery platform leverages a broad network of international collaborations and established research infrastructures at leading European institutions. Capabilities include a BSL-3/P3 laboratory for advanced viral assays, Cryo-EM expertise for rapid viral protein characterization, and an antibody discovery platform that has already generated Aerium’s promising lead monoclonal antibodies.

Our team


Board of Directors



Contact us

Message Us

    Back to top